Xytis Enrolls First Patient in Phase II Clinical Study with Anatibant (XY2405) for Traumatic Brain Injury
Xytis announced it has enrolled the first patient in the Company's Phase II clinical trial with Anatibant for the treatment of traumatic brain injury (TBI). "We plan to enroll 400 patients with moderate to severe closed head TBI in 9 countries over the next 12 months," said Vincent F. Simmon, Ph.D., President and CEO of Xytis. "We are working with the London School of Hygiene and Tropical Medicine (LSHTM), which has considerable and unique experience in enrolling patients with TBI in highly-recruiting centers throughout the world. Patients with moderate to severe TBI will receive one of three doses of anatibant or placebo for 5 days. Endpoints for the trial include safety and tolerability, mortality as well as functional assessment at days 6 and 15 post-injury."
